Patents by Inventor Thierry Abribat
Thierry Abribat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11192932Abstract: The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.Type: GrantFiled: May 23, 2019Date of Patent: December 7, 2021Assignee: Amolyt PharmaInventors: Thomas Delale, Stephane Milano, Thierry Abribat, David Clemmons
-
Publication number: 20210348151Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: ApplicationFiled: June 3, 2021Publication date: November 11, 2021Inventor: Thierry ABRIBAT
-
Publication number: 20210196789Abstract: The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.Type: ApplicationFiled: May 23, 2019Publication date: July 1, 2021Inventors: Thomas DELALE, Stephane MILANO, Thierry ABRIBAT, David CLEMMONS
-
Patent number: 11046946Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine amino hydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight of about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: GrantFiled: May 18, 2020Date of Patent: June 29, 2021Assignee: JAZZ PHARMACEUTICALS II SASInventor: Thierry Abribat
-
Patent number: 10947285Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.Type: GrantFiled: February 5, 2018Date of Patent: March 16, 2021Assignee: Amolyt PharmaInventors: David Clemmons, Gang Xi, Thomas Delale, Michel Julien, Thierry Abribat
-
Publication number: 20200347374Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: ApplicationFiled: May 18, 2020Publication date: November 5, 2020Inventor: Thierry ABRIBAT
-
Publication number: 20190359676Abstract: The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.Type: ApplicationFiled: May 23, 2019Publication date: November 28, 2019Inventors: Thomas DELALE, Stephane MILANO, Thierry ABRIBAT, David CLEMMONS
-
Publication number: 20190352358Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.Type: ApplicationFiled: February 5, 2018Publication date: November 21, 2019Inventors: David CLEMMONS, Gang XI, Thomas DELALE, Michel JULIEN, Thierry ABRIBAT
-
Publication number: 20180346900Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: ApplicationFiled: February 1, 2018Publication date: December 6, 2018Applicant: Jazz Pharmaceuticals II SASInventor: Thierry Abribat
-
Publication number: 20180230191Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.Type: ApplicationFiled: February 5, 2018Publication date: August 16, 2018Inventors: David Clemmons, Gang Xi, Thomas Delale, Michel Julien, Thierry Abribat
-
Patent number: 9920311Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: GrantFiled: August 5, 2015Date of Patent: March 20, 2018Assignee: Jazz Pharmaceuticals II SASInventor: Thierry Abribat
-
Patent number: 9550821Abstract: A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.Type: GrantFiled: December 14, 2012Date of Patent: January 24, 2017Assignee: Alize Pharma SASInventors: Aart Jan Van Der Lely, Thierry Abribat
-
Publication number: 20160060613Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: ApplicationFiled: August 5, 2015Publication date: March 3, 2016Applicant: ALIZE PHARMA II SASInventor: Thierry Abribat
-
Publication number: 20140336109Abstract: A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.Type: ApplicationFiled: December 14, 2012Publication date: November 13, 2014Applicant: Alize Pharma SASInventors: Aart Jan Van Der Lely, Thierry Abribat
-
Patent number: 8481489Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: July 9, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8435945Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: May 7, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8314066Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 23, 2007Date of Patent: November 20, 2012Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Publication number: 20120100121Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: ApplicationFiled: July 6, 2010Publication date: April 26, 2012Inventor: Thierry Abribat
-
Publication number: 20120004174Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: July 7, 2011Publication date: January 5, 2012Applicant: THERATECHNOLOGIES INC.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Patent number: RE49736Abstract: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.Type: GrantFiled: March 18, 2020Date of Patent: November 28, 2023Assignee: Jazz Pharmaceuticals II SASInventor: Thierry Abribat